ANTIBODY-DRUG CONJUGATE TARGETED THERAPY
Enhertu is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with unresectable (cannot be surgically removed) or metastatic HER2-postive breast cancer who have received at least two other therapies. Enhertu is also referred to by its drug name, fam-trastuzumab deruxtecan-nxki.
Enhertu is used as an immune targeted therapy for breast cancer. Enhertu is a combination of drugs belonging to the classes of drugs called HER2-directed antibodies and topoisomerase inhibitor conjugates. Enhertu is believed to work by binding to cancer cells and causing cell death from within.
How do I take it?
Prescribing information states that Enhertu is given as an intravenous infusion (slow injection into your vein) by a health care professional. Enhertu is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.
Enhertu is available only as an intravenous infusion.
The FDA-approved label for Enhertu lists common side effects including nausea, fatigue, vomiting, hair loss, constipation, decreased appetite, anemia (low red blood cell count), neutropenia (low white blood cell count), diarrhea, cough, and thrombocytopenia (low blood platelet count).
Rare but serious side effects listed for Enhertu include heart failure.
For more details about this treatment, visit:
Enhertu — Daiichi-Sankyo and Aztrazeneca
Enhertu — Breastcancer.org